Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Heel Wedges and Carbon Fiber Custom Dynamic Orthoses to Control Knee Biomechanics [NA]
Clinical trial update on heel wedges and carbon fiber dynamic orthoses to control knee biomechanics; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-01-16Clinical Trial Update: Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia [Phase 2, Phase 3]
Phase 2/3 clinical trial investigating allogeneic stem cell transplantation for children and adolescents with acute lymphoblastic leukemia i…
-
FDA approval · 2024-01-05FDA Approved: IMATINIB MESYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application from Mylan Pharmaceuticals for imatinib mesylate, enabling a generic version to be marketed under AN…
-
CLINICAL_TRIALS trial_result · 2023-12-29Clinical Trial Update: A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL) [Phase 2]
A Phase 2 rollover study provided continued treatment with lyophilized pegaspargase (S95014) in pediatric patients with acute lymphoblastic …
-
CLINICAL_TRIALS trial_result · 2023-12-05Clinical Trial Update: Iterative Design of Custom Dynamic Orthoses [NA]
This update reports the completion of a clinical trial (NCT04800510) evaluating iterative design of custom dynamic orthoses in adults with a…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-12-04Clinical Trial Update: Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL [Phase 1, Phase 2]
A phase 1/2 clinical trial investigated patient-individualized peptide vaccination targeting tumor-specific mutations in children and young …
-
FDA label_change · 2023-11-29FDA Approved: ASPARLAS — Supplemental Application (Servier Pharmaceuticals LLC)
FDA approved a supplemental application for ASPARLAS (calaspargase pegol) from Servier Pharmaceuticals LLC, resulting in changes to the prod…
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients [Phase 4]
Phase 4 trial updates two doses of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia in transplant-eligible patients…
-
CLINICAL_TRIALS trial_result · 2023-11-21Clinical Trial Update: Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT [Phase 2]
Phase 2 clinical trial update evaluating plerixafor in combination with donor lymphocyte infusion for relapsed acute leukemia after allogene…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) [Phase 2, Phase 3]
Open-label study of JZP-458 (RC-P) in acute lymphoblastic leukemia and lymphoblastic lymphoma completed; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-11-15Clinical Trial Update: Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia [Phase 2]
Phase 2 pediatric trial evaluating Isatuximab in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia or acute…
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients [Phase 1, Phase 2]
Prospective clinical study evaluating bridging alloHSCT after obinutuzumab with chidamide and venetoclax in relapsed/refractory Philadelphia…
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis [Phase 3]
Phase 3 clinical trial evaluating a post-transplant immunomodulatory regimen (cyclophosphamide, abatacept, vedolizumab, and a calcineurin in…
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Methods of T Cell Depletion Trial (MoTD) [Phase 2]
Phase 2 trial update for methods of T cell depletion in various hematologic malignancies is ongoing.
-
CLINICAL_TRIALS trial_result · 2023-09-26Clinical Trial Update: Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study [Phase 1, Phase 2]
Long-term follow-up update from BP-004 study (Phase 1/Phase 2) by Bellicum Pharmaceuticals; study status TERMINATED with results posted in 2…
-
FDA approval · 2023-09-22FDA Approved: DASATINIB — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for dasatinib by Apotex Corp. The approval allows the generic product to be marketed.
-
CLINICAL_TRIALS trial_result · 2023-09-14Clinical Trial Update: A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor [Phase 2]
Phase II trial evaluating safety and efficacy of subcutaneous plerixafor in related donors of peripheral blood stem cells for various hemato…
-
CLINICAL_TRIALS trial_result · 2023-09-06Clinical Trial Update: Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL [Phase 2]
Phase 2 trial evaluating inotuzumab ozogamicin combined with chemotherapy in older patients with Ph-negative CD22+ B-cell precursor ALL is o…
-
FDA approval · 2023-08-29FDA Approved: CLOFARABINE — Supplemental Application (Dr.Reddy's Laboratories Inc)
FDA approved a supplemental application for clofarabine from Dr. Reddy's Laboratories Inc, marking an approved update to the generic drug's …
-
CLINICAL_TRIALS trial_result · 2023-08-16Clinical Trial Update: A Study for Older Adults With Acute Lymphoblastic Leukaemia [Phase 2]
Phase 2 trial update for older adults with acute lymphoblastic leukemia completed.
-
FDA approval · 2023-08-16FDA Approved: IMATINIB — Supplemental Application (Dr.Reddy's Laboratories Inc)
FDA approved a supplemental application for Imatinib from Dr. Reddy's Laboratories Inc, resulting in regulatory approval for a change to the…
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating ibrutinib to prevent acute leukemia after reduced-intensity conditioning and stem cell transplant.
-
CLINICAL_TRIALS trial_result · 2023-07-05Clinical Trial Update: A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL) [Phase 2]
Phase 2 trial comparing liquid vs. lyophilized pegylated asparaginase (S95014) formulations in pediatric acute lymphoblastic leukemia; study…
-
CLINICAL_TRIALS trial_result · 2023-06-26Clinical Trial Update: Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies [EARLY_Phase 1]
Early-phase trial investigating irradiated donor cells after stem cell transplant to control cancer in patients with hematologic malignancie…
-
FDA approval · 2023-06-20FDA Approved: BLINCYTO — Supplemental Application (Amgen, Inc)
The FDA approved Amgen's supplemental application for BLINCYTO (blinatumomab), updating the product's labeling and/or indication.